QuidelOrtho Corp (QDEL): Capital Expenditures
$188.20M
Year ended 2025-12-28
$154.00M
Trailing 12 months to 2026-06-28
+10.1%
3-year compound annual growth
+23.7%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-28 | $188.20M | -3.5% | 2026-02-19, From 2024-12-30 |
| 2024-12-29 | $195.10M | -6.8% | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | $209.30M | +48.5% | 2026-02-19, From 2023-01-02 |
| 2023-01-01, Fiscal 2022 | $140.90M | -51.9% | 2025-02-27, From 2022-01-03 |
| 2022-01-02, Fiscal 2021 | $292.80M | +351.2% | 2024-08-01, From 2021-01-04 |
| 2021-01-03, Fiscal 2020 | $64.90M | n/a | 2023-02-23, From 2019-12-30 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | 2025-12-28 | $188.20M | -3.5% |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $124.68M | +3.1% |
| Neogen Corp (NEOG) | 2026-05-31 | $51.30M | -51.0% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $1.13M | -80.5% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $1.15M | +2.0% |
| Immucell Corp (ICCC) | 2025-12-31 | $1.25M | +168.5% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $16.0K | -56.8% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $3.19M | +517.2% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $89.6K | -67.7% |
Compare QDEL, IDXX, NEOG, NTLA side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗